Technical Analysis for GNCA - Genocea Biosciences, Inc.

Grade Last Price % Change Price Change
grade F 2.05 -5.09% -0.11
GNCA closed down 5.09 percent on Wednesday, November 13, 2019, on 2.25 times normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical GNCA trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -5.09%
Expansion Breakdown Bearish Swing Setup -5.09%
Lower Bollinger Band Walk Weakness -5.09%
New 52 Week Low Weakness -5.09%

Older signals for GNCA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Genocea Biosciences, Inc., a clinical stage biotechnology company, discovers and develops novel vaccines to treat infectious diseases. The company, through its proprietary discovery platform, AnTigen Lead Acquisition System (ATLAS), designs vaccines that stimulate T cell immunity. The company primarily develops GEN-003, a candidate therapeutic vaccine or immunotherapy, which is in Phase 1/2a trial to treat herpes simplex virus-2 or HSV-2 infections; and GEN-004, a T cell vaccine candidate that is in Phase 1 trial to prevent infections caused by pneumococcus. It also develops earlier-stage programs for chlamydia, HSV-2 prophylaxis, and malaria. The company, formerly known as Genocea, Inc., was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Biotechnology Medical Specialties Infectious Diseases Immunotherapy Vaccination Microbiology Infections Vaccine Herpes Simplex Virus Malaria Herpes Simplex Sexually Transmitted Diseases And Infections Herpes Simplex Research Viruses
Is GNCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.28
52 Week Low 1.99
Average Volume 119,909
200-Day Moving Average 4.2086
50-Day Moving Average 2.851
20-Day Moving Average 2.4775
10-Day Moving Average 2.388
Average True Range 0.1778
ADX 37.2
+DI 12.5673
-DI 29.9413
Chandelier Exit (Long, 3 ATRs ) 2.2531
Chandelier Exit (Short, 3 ATRs ) 2.5234
Upper Bollinger Band 2.7961
Lower Bollinger Band 2.1589
Percent B (%b) -0.17
BandWidth 25.719475
MACD Line -0.1627
MACD Signal Line -0.1368
MACD Histogram -0.0259
Fundamentals Value
Market Cap 58.69 Million
Num Shares 28.6 Million
EPS -2.04
Price-to-Earnings (P/E) Ratio -1.00
Price-to-Sales 0.00
Price-to-Book 1.80
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.41
Resistance 3 (R3) 2.43 2.33 2.35
Resistance 2 (R2) 2.33 2.24 2.32 2.33
Resistance 1 (R1) 2.19 2.18 2.14 2.17 2.31
Pivot Point 2.09 2.09 2.07 2.08 2.09
Support 1 (S1) 1.95 2.00 1.90 1.93 1.79
Support 2 (S2) 1.85 1.94 1.84 1.77
Support 3 (S3) 1.71 1.85 1.75
Support 4 (S4) 1.69